ACE and hydrops fetalis: In HF patients with reduced ejection fraction (HFrEF), LCZ696 was reported to be more effective than enalapril in reducing hospitalization and cardiovascular and sudden death, preventing HF progression and improving renal function, as well as quality of life, in the Prospective comparison of ARNI with the ACE inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial [103,104,105,106].